- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Chip Kahn Is Cautious About Part B Demonstration
The newly proposed Medicare Part B payment demonstration met immediate criticism from some in the healthcare industry. Chip Kahn, president and CEO of the Federation of American Hospitals, is also very hesitant about the demonstration and worries that it might be premature.
The newly proposed Medicare Part B payment demonstration met immediate criticism from some in the healthcare industry. Chip Kahn, president and CEO of the Federation of American Hospitals, is also very hesitant about the demonstration and worries that it might be premature.
Transcript (modified)
What is your take on the newly proposed Medicare Part B payment demonstration?
It’s going to take a lot of analysis on our part to see whether or not, from a hospital standpoint, this is going to be good for the patients and helpful in terms of the decision making in hospitals. And it’s very complicated.
What worries me about this is that there is some imperative to get this demonstration applied nationally and I think it’s premature. I think we need to test this out because no matter how good the analytics on the implications of it, until you actually test out a new program you’re not going to know how it’s really going to work and what the unintended consequences of it may be.
And I’m really reticent. From our standpoint this is too different from the way the payment is done now for us to just jump in. We’re really going to have to do a lot of analysis on it.
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More
The Legal Architecture of Psychedelic Therapy: Risks, Responsibilities, and Reimbursement Realities
July 30th 2025Key legal, ethical, and compliance considerations for managed care professionals navigating the evolving landscape of psychedelic-assisted therapy include regulatory risks, data privacy challenges, reimbursement limitations, and the need for culturally informed care models.
Read More
